Methods for modulating mannose content of recombinant proteins

What is this patent about?

’435 is related to the field of recombinant glycoprotein production, specifically focusing on the post-translational modification of N-linked glycosylation. In the manufacturing of therapeutic antibodies, the presence of high-mannose oligosaccharides—those containing more than four mannose residues—is often undesirable because these structures can lead to faster clearance from the bloodstream and increased immunogenicity. The background context involves the challenge of controlling these glycan profiles within mammalian cell culture systems to ensure the safety and efficacy of the resulting biologic drugs.

The underlying idea behind ’435 is that the mannose content of a recombinant protein is not just a function of the host cell's genetic machinery, but is significantly influenced by the physical and chemical environment of the cell culture. The inventors discovered a direct correlation between high osmolality and the accumulation of high-mannose species. By maintaining the culture medium within a specific, lower osmotic pressure range and carefully selecting the chemical constituents of the feed, the invention effectively forces the cell's internal processing pathways to favor the production of low-mannose glycoproteins.

The claims of ’435 focus on a method for producing recombinant antibodies or fragments by maintaining a culture medium with an osmolality of approximately 400 mOsm/Kg or less. The independent claims require a specific combination of environmental controls: limiting potassium to 70 mM or less and sodium to 200 mM or less, ensuring the medium is substantially free of specific amino acids like alanine and glutamic acid, and incorporating an osmoprotectant such as betaine. The technical result defined by the claims is a composition where fewer than 10% of the antibody molecules possess more than four mannose residues.

In practice, the invention works by manipulating the concentration of salts and nutrients to prevent osmotic stress, which otherwise disrupts the fixed order of enzyme-mediated mannose removal in the Golgi apparatus. The addition of betaine at concentrations between 20 mM and 30 mM serves as a critical buffer against osmotic fluctuations, allowing the cells to maintain efficient glycan processing even as metabolic byproducts accumulate. This environmental stabilization ensures that the core oligosaccharide structure is successfully trimmed down to four or fewer mannose residues before the protein is secreted.

This approach differs from prior methods that relied primarily on genetic engineering of the host cell or complex downstream purification to remove high-mannose variants. Instead, ’435 provides a process-driven solution that achieves a low-mannose profile through media formulation and physical parameter control. By specifically excluding certain amino acids and tightly regulating the ionic strength of the medium, the method provides a scalable way to produce therapeutic antibodies with superior pharmacokinetic properties without the need for altering the cell's fundamental glycosylation enzymes.